Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319860 · ClinicalTrials.gov registry record · Phase 2
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05319860 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 100 participants.
The verdict
NCT05319860, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
Interventions
- DRUG Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)
- DRUG Aromatherapy Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319860
The ClinicalTrials.gov registry entry for NCT05319860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV) is the first listed.
NCT05319860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05319860 about?
NCT05319860 is a clinical study titled "Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)". The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
What is the current status of trial NCT05319860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-08-01. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05319860?
The interventions under investigation include: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV) (DRUG), Aromatherapy Care (DRUG).
Who is sponsoring clinical trial NCT05319860?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.